title: NEUROBID--an EU-funded project to study the developing brain barriers.
abstract: Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to euro386 billion. Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe's total disease burden. In the treatment of neurological disease, the blood brain barrier (BBB) still represents an obstacle for the delivery of drugs to the brain and thus a major challenge for the development of therapeutic regimens. Understanding the molecular basis and functioning of the BBB in health and disease, including transport mechanisms across the BBB, therefore holds significant potential for future strategies to prevent and ameliorate neurological disease. Recent research indicates that some neurological disorders have a developmental etiologic component. The major goal of the NEUROBID project is thus to understand the molecular mechanisms and function of the BBB in health and disease both in the developing brain and the adult central nervous system. With an interdisciplinary consortium from the fields of developmental neurobiology and BBB research, NEUROBID aims to (i) understand the involvement of normal and disturbed BBB function in normal and abnormal brain development and (ii) to develop novel strategies for drug delivery to the brain. Unique transport mechanisms across the BBB will be used to target potential therapeutic macromolecular and cellular agents specifically to the brain barriers and transport them into the brain. The main target disorders of NEUROBID are non-inherited neurodevelopmental disorders arising from perinatal adverse exposure, such as cerebral palsy, and classic adult neurological disorders such as multiple sclerosis and stroke. In the long term, NEUROBID hopes to pave the way for new treatment strategies and thus reduce the economic and social burden of neurological disease.
authors.affiliation: Hannover Medical School, Hannover, Germany. bueter.wolfgang@mh-hannover.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Bueter
authors.forename: Norman R
authors.initials: NR
authors.lastname: Saunders
authors.forename: Carina
authors.initials: C
authors.lastname: Mallard
authors.forename: Hans-Christian
authors.initials: HC
authors.lastname: Bauer
authors.forename: Helen B
authors.initials: HB
authors.lastname: Stolp
authors.forename: Annemieke
authors.initials: A
authors.lastname: Kavelaars
authors.forename: Olaf
authors.initials: O
authors.lastname: Dammann
mesh_terms: D000328:Adult; D001812:Blood-Brain Barrier / Q000502:physiology / Q000503:physiopathology*; D001927:Brain Diseases / Q000188:drug therapy* / Q000191:economics; D002648:Child; D002658:Developmental Disabilities / Q000188:drug therapy / Q000191:economics; D005062:European Union / Q000191:economics; D014943:Global Health; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D033183:Interdisciplinary Communication; D010348:Patient Care Team / Q000191:economics; D012109:Research Support as Topic / Q000379:methods / Q000458:organization & administration / Q000639:trends*